Predrag Stojadinovic

Dr. Predrag Stojadinovic

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
PSPredrag Stojadinovic
Predrag Stojadinovic
DWDan Wichterle
Dan Wichterle
PPPetr Peichl
Petr Peichl
HNHiroshi Nakagawa
Hiroshi Nakagawa
RČRobert Čihák
Robert Čihák
JKJosef Kautzner
Josef Kautzner

2 July 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
PPPetr Peichl
Petr Peichl
ABAlan Bulava
Alan Bulava
DWDan Wichterle
Dan Wichterle
FSFilip Schlosser
Filip Schlosser
PSPredrag Stojadinovic
Predrag Stojadinovic
JKJosef Kautzner
Josef Kautzner
Aims: A pulsed electric field (PF) energy source is a novel potential option for catheter ablation of ventricular arrhythmias (VAs) as it can create deeper lesions, particularly in scarred tissue. However, very limited data exist on its efficacy and safety. This prospective observational study reports the initial experience with VA ablation using focal PF. Methods and results: The study population consisted of 44 patients (16 women, aged 61 ± 14years) with either frequent ventricular premature complexes (VPCs, 48%) or scar-related ventricular tachycardia (VT, 52%). Ablation was performed using an irrigated 4 mm tip catheter and a commercially available PF generator. On average, 16 ± 15 PF applications (25 A) were delivered per patient. Acute success was achieved in 84% of patients as assessed by elimination of VPC or reaching non-inducibility of VT. In three cases (7%), a transient conduction system block was observed during PF applications remotely from the septum. Root analysis revealed that this event was caused by current leakage from the proximal shaft electrodes in contact with the basal interventricular septum. Acute elimination of VPC was achieved in 81% patients and non-inducibility of VT in 83% patients. At the 3-month follow-up, persistent suppression of the VPC was confirmed on Holter monitoring in 81% patients. In the VT group, the mean follow-up was 116 ± 75 days and a total of 52% patients remained free of any VA. Conclusion: Pulsed electric field catheter ablation of a broad spectrum of VA is feasible with acute high efficacy; however, the short-term follow-up is less satisfactory for patients with scar-related VT.

13 October 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
PSPredrag Stojadinovic
Predrag Stojadinovic
NVNicoletta Ventrella
Nicoletta Ventrella
HAHana Alfredová
Hana Alfredová
DWDan Wichterle
Dan Wichterle
PPPetr Peichl
Petr Peichl
JKJosef Kautzner
Josef Kautzner
Introduction: Pulsed electric field (PEF) has emerged as a promising energy source for catheter ablation of atrial fibrillation (AF). However, data regarding the in‐vivo effect of PEF energy on erythrocytes during AF ablation procedures are scarce. This study aimed to quantify the impact of PEF energy on erythrocyte damage during AF ablation by assessing specific hemolytic biomarkers.Methods: A total of 60 patients (age: 68 years, males: 72%, serum creatinine: 91 µmol/L) with AF underwent catheter ablation of AF using PEF energy delivered by a multipolar pentaspline Farawave catheter (Farapulse, Boston Scientific, Inc.). Ablation beyond pulmonary vein isolation was performed at the operator's discretion. Peripheral venous blood was sampled for assessing the plasma levels of free hemoglobin (fHb), direct (conjugated) bilirubin, lactate dehydrogenase (LDH), and creatinine before, immediately after the ablation, and on the next day.Results: Following the PEF ablation with duration of [median (interquartile range)] 75 (58, 95) min, with 74 (52, 92) applications and PVI only in 27% of patients, fHb, LDH, and direct bilirubin significantly increased, from 40 (18, 65) to 493 (327, 848) mg/L, from 3.1 (2.6, 3.6) to 6.8 (5.0, 7.9) µkat/L, and from 12 (9, 17) to 28 (16, 44) µmol/L, respectively (all p < .0001). A strong linear correlation was found between the peak fHb and the number of PEF applications (R = 0.81, p < .001). The major hemolysis (defined as fHb >500 mg/L) was predicted by the number of PEF applications with the corresponding area under the receiver operating characteristic curve of 0.934. The optimum cut‐off value of >74 PEF applications predicted the major hemolysis with 89% sensitivity and 87% specificity.Conclusion: Catheter ablation of AF using PEF energy delivered from a pentaspline catheter is associated with significant intravascular hemolysis. More than 74 PEF applications frequently resulted in major hemolysis. However, the critical amount of PEF energy that may cause kidney injury in susceptible patients remains to be investigated.

31 October 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
PPPetr Peichl
Petr Peichl
DWDan Wichterle
Dan Wichterle
FSFilip Schlosser
Filip Schlosser
PSPredrag Stojadinovic
Predrag Stojadinovic
VNVojtěch Nejedlo
Vojtěch Nejedlo
JKJosef Kautzner
Josef Kautzner
Aims: Catheter ablation is an effective treatment method for recurrent ventricular tachycardias (VTs). However, at least in part, procedural and clinical outcomes are limited by challenges in generating an adequate lesion size in the ventricular myocardium. We investigated procedural and clinical outcomes of VT ablation using a novel ‘large-footprint’ catheter that allows the creation of larger lesions either by radiofrequency (RF) or by pulsed field (PF) energy. Methods and results: In prospectively collected case series, we describe our initial experience with VT ablation using a lattice-tip, dual-energy catheter (Sphere-9, Medtronic), and a compatible proprietary electroanatomical mapping system (Affera, Medtronic). The study population consisted of 18 patients (aged 55 ± 15 years, one woman, structural heart disease: 94%, ischaemic heart disease: 56%, left ventricular ejection fraction: 34 ± 10%, electrical storm: 22%) with recurrent sustained VTs and ≥1 previously failed endocardial RF ablation with conventional irrigated-tip catheter in 66% of patients. On average, 12 ± 7 RF and 8 ± 9 PF applications were delivered per patient. In three-fourths of patients undergoing percutaneous epicardial ablation, spasms in coronary angiography were observed after PF applications. All resolved after intracoronary administration of nitrates. No acute phrenic nerve palsy was noted. One patient suffered from a stroke that resolved without sequelae. Post-ablation non-inducibility of VT was achieved in 89% of patients. Ventricular-arrhythmia-free survival at three months was 78%. Conclusion: VT ablation using a dual-energy lattice-tip catheter and a novel electroanatomical mapping system is feasible. It allows rapid mapping and effective substrate modification with good outcomes during short-term follow-up.

18 September 2022 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PSPredrag Stojadinovic
Predrag Stojadinovic
ADAslesha Deshraju
Aslesha Deshraju
DWDan Wichterle
Dan Wichterle
MFMasato Fukunaga
Masato Fukunaga
PPPetr Peichl
Petr Peichl
MŠMarek Šramko
Marek Šramko

2 July 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
JKJosef Kautzner
Josef Kautzner
JHJana Hašková
Jana Hašková
PSPredrag Stojadinovic
Predrag Stojadinovic
PPPetr Peichl
Petr Peichl
DWDan Wichterle
Dan Wichterle
Catheter ablation (CA) has become an established treatment strategy for managing recurrent ventricular tachycardias (VTs) in patients with structural heart disease. In recent years, percutaneous mechanical circulatory support (PMCS) devices have been increasingly used intra-operatively to improve the ablation outcome. One indication would be rescue therapy for patients who develop haemodynamic deterioration during the ablation. However, more efforts are focused on identifying subjects who are at high risk of such deterioration and could benefit from the pre-emptive use of the PMCS. The third reason to use PMCS could be the inability to identify diffuse substrate, especially in non-ischaemic cardiomyopathy. This paper reviews available experiences using various types of PMCS in different clinical scenarios. Although PMCS allows mapping during VT, it does not significantly influence acute outcomes and not convincingly long-term outcomes. On the contrary, the complication rate appears to be higher in PMCS cohorts. Our data suggest that even in patients with severe left ventricular dysfunction, the substrate modification can be performed without the need for general anaesthesia and risk of haemodynamic decompensation. In end-stage heart failure associated with the electrical storm, implantation of a left ventricular assist device (or PMCS with a transition to the left ventricular assist device) might be the preferred strategy before CA. In high-risk patients who are not potential candidates for these treatment options, radiotherapy could be considered as a bail-out treatment of recurrent VTs. These approaches should be studied in prospective trials.